Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nichi-Iko Rolls Out Remicade Biosimilar
Japanese generic major Nichi-Iko Pharmaceutical launched its biosimilar version of Remicade (infliximab) in Japan on November 29 upon its NHI price listing on the same day. It is the first biosimilar for Nichi-Iko and the second follow-on for the big-seller…
To read the full story
Related Article
- Remicade Biosimilar Gets New Dosage Nod for Psoriasis, Crohn’s Disease: Nichi-Iko/Ayumi
June 21, 2018
- Nichi-Iko Earns Remicade Biosimilar Nod, Picks GI-Savvy Zeria as Copromotion Ally
September 28, 2017
- Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
September 19, 2017
- Nichi-Iko’s Remicade Biosimilar Filed in 2 Routes, Ayumi to Also Market It under Different Trade Name
July 14, 2017
BUSINESS
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Astellas Kicks Off Global PIII of KRAS G12D Degrader Setidegrasib
April 16, 2026
- G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…